Registering New Drugs for Low-Income Countries: The African Challenge
Open accessThe DOI matches its Crossref record; 4 of the 5 references it cites were found in a registry or an index.
Abstract
The Policy Forum allows health policy makers around the world to discuss challenges and opportunities for improving
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other challenges in the medicine registration process include noncompliance with medicine registration guidelines in different countries, prolonged medicine registration time or dossier rejection, poor medicine dossier assessment, cost of current good manufacturing practice inspection, and quality testing procedures that did not keep pace with the increasing demand of pharmaceutical industries for”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [38]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other challenges in the medicine registration process include noncompliance with medicine registration guidelines in different countries, prolonged medicine registration time or dossier rejection, poor medicine dossier assessment, cost of current good manufacturing practice inspection, and quality testing procedures that did not keep pace with the increasing demand of pharmaceutical industries for”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [38]
Experimental — accuracy not yet measuredIn the citing paper
“Other challenges in the medicine registration process include noncompliance with medicine registration guidelines in different countries, prolonged medicine registration time or dossier rejection, poor medicine dossier assessment, cost of current good manufacturing practice inspection, and quality testing procedures that did not keep pace with the increasing demand of pharmaceutical industries for”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [38]
In the citing paper
“Other challenges in the medicine registration process include noncompliance with medicine registration guidelines in different countries, prolonged medicine registration time or dossier rejection, poor medicine dossier assessment, cost of current good manufacturing practice inspection, and quality testing procedures that did not keep pace with the increasing demand of pharmaceutical industries for”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [38]
In the citing paper
“Other challenges in the medicine registration process include noncompliance with medicine registration guidelines in different countries, prolonged medicine registration time or dossier rejection, poor medicine dossier assessment, cost of current good manufacturing practice inspection, and quality testing procedures that did not keep pace with the increasing demand of pharmaceutical industries for”
From Challenges to the Availability and Affordability of Essential Medicines in African Countries: A Scoping Review (2023) · cites this paper as [38]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zijlstra, E. E., & El-Hassan, A. M. (2001) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(01)90218-4 · Cited by 494
Developing ANDI: A Novel Approach to Health Product R&D in Africa
Nwaka, S., Ilunga, T. B., Da Silva, J. S., Rial Verde, E., Hackley, D., De Vré, R., Mboya-Okeyo, T., & Ridley, R. G. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000293 · Cited by 70 · cited 1×
“The WHO, as a credible and trusted multilateral agency, can potentially play a large role in leading these efforts, as seen in recent pan-African initiatives such as the African Network for Drugs & Diagnostics Innovation [10].”
BackgroundRegistering new drugs: the African context.
Morán, M. E. C., Guzman, J. Z., McDonald, A. E., Wu, L., & Omune, B. (2010) · Cited by 11
Self-citationOnce-daily dosage lamivudine another ARV first for Cipla Medpro
Editorial Office (2008) · South African Family Practice · doi:10.1080/20786204.2008.10873658 · Cited by 3
Research works printed but not linked: 1
- 2008, Novartis receives FDA priority review for Coartem®, potentially the first artemisinin-based combination treatment (ACT) for malaria in the US [press release].
Cited by
Yenet, A., Nibret, G., & Tegegne, B. A. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s413546 · Cited by 202
“In response to pharmaceutical-related crises, drug regulation has evolved over the last 50 years (Moran et al 2011).”
Medicines Regulation in Africa: Current State and Opportunities
Ndomondo-Sigonda, M., Miot, J., Naidoo, S., Dodoo, A., & Kaale, E. A. (2017) · Pharmaceutical Medicine · doi:10.1007/s40290-017-0210-x · Cited by 179
“Studies also show that the growing demand to assess novel neglecteddisease products for African use have necessitated the establishment of various regulatory pathways to facilitate approval including the European Medicines Agency (EMA) Article 58; the WHO Prequalification Scheme; and the United States Food and Drug Ad…”
BackgroundWhy miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most
Sunyoto, T., Potet, J., & Boelaert, M. (2018) · BMJ Global Health · doi:10.1136/bmjgh-2018-000709 · Cited by 160
Chan, A. Y. L., Chan, V. K. Y., Olsson, S., Fan, M., Jit, M., Gong, M., Zhang, S., Ge, M., Pathadka, S., Chung, C. C. Y., et al. (2020) · Value in Health · doi:10.1016/j.jval.2020.06.020 · Cited by 112
“To facilitate timely patient access to orphan drugs, countries/areas may consider leveraging the WHO prequalification approval and parallel or twinned approval with the help of foreign competent authorities to uphold regulatory standards.(36) Countries/areas may subsidize patients’ cross-border health treatment if the…”
BackgroundTreatment options for second-stage gambiense human African trypanosomiasis
Éperon, G., Balasegaram, M., Potet, J., Mowbray, C. E., Valverde, O., & Chappuis, F. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.959496 · Cited by 102
“The new global regulatory mechanisms designed for drugs for NTDs, including Article 58 of the EMA, could be used in the future to fast-track the registration of new drugs for HAT with the contribution of experts from both European and African regulatory agencies [54].”
Background
Metadata
- Authors
- Moran, M., Strub-Wourgaft, N., Guzman, J., Boulet, P., Wu, L., & Pecoul, B.
- Affiliations
- Policy Cures (AU)
- Drugs for Neglected Diseases Initiative (CH)
- Corresponding author
- Moran, Mary
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-02-01
- Volume
- 8
- Issue
- 2
- Pages
- e1000411
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- PMC
- PMC3051317
- OpenAlex
- W2073360669
- Cited by
- 44
- References
- 5
- Citations by year
- 2026: 2 · 2025: 2 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 4 · 2017: 3 · 2016: 2 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 6
- FWCI
- 12.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Wellcome Trust
- National Institute for Health and Care Research
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pharmaceutical Quality and Counterfeiting
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Keywords
- drug registration, new drugs, low-income countries, Africa, drug regulation, access to medicines, health policy
- MeSH terms
- Africa, Developing Countries, Humans, Poverty, Registries, Drug Approval, Government Regulation, Neglected Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Registering New Drugs for Low-Income Countries: The African Challenge. https://app.cochat.ai/papers/10.1371/journal.pmed.1000411
- The paper
- Moran, M., Strub-Wourgaft, N., Guzman, J., Boulet, P., Wu, L., & Pecoul, B. (2011). Registering New Drugs for Low-Income Countries: The African Challenge. PLoS Medicine. https://doi.org/10.1371/journal.pmed.1000411
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
![Figure 1 Neglected disease drug registration timeline [7],[9],[11]–[19]. Additional source: correspondence with Novartis.](https://figures.cochat.ai/paper-figures/56de14781c024948abd1948f1e9241d0/registering-new-drugs-for-low-income-countries-the-african-challenge-figure-1.jpg)
![Figure 2 WHO prequalified drugs by disease [7].](https://figures.cochat.ai/paper-figures/fc9b990d4e8a40df92a1cb98437e76f7/registering-new-drugs-for-low-income-countries-the-african-challenge-figure-2.jpg)